Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 14 Fallopian Tube Neoplasms 13 Neoplasms 9 Breast Neoplasms 8 Prostatic Neoplasms 7 Carcinoma, Ovarian Epithelial 7 Endometrial Neoplasms 5 Pancreatic Neoplasms 4 Uterine Cervical Neoplasms 3 Recurrence 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Neoplasm Metastasis 2 Metastatic Castration Resistant Prostate Cancer 2 Lung Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1 Prostate Cancer Metastatic 1 Primary Myelofibrosis 1 Pathologic Complete Response 1 Myeloproliferative Disorders 1

Interventions

enzalutamide 7 Prednisone 7 cabazitaxel 6 Radiosurgery 6 Docetaxel 5 Androgen Antagonists 4 Abiraterone Acetate 4 XRP6258 2 Standard of Care 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 pembrolizumab 1 olaparib 1 gallium 68 PSMA-11 1 fludrocortisone acetate 1 darolutamide 1 apalutamide 1 Zuclomiphene 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisolone 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Midazolam 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 LY3023414 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × rucaparib × Clear all

NCT03413995 2024-10-16

TRIUMPH

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

12 enrolled 11 charts

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡